On December 6, Loxo Oncology (LOXO) received its first milestone payment pursuant to its collaboration with Bayer (BAYRY), equal to $275M, which was earned upon the grant of U.S. Food and Drug Administration marketing approval for Vitrakvi, larotrectinib.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.